ইঙ্গিত
Genib is used as the first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) whose tumours carry epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as confirmed by an FDA-approved test.
⚠️ কোনো ওষুধ গ্রহণের আগে সর্বদা নিবন্ধিত চিকিৎসকের পরামর্শ নিন।
ফার্মাকোলজি
Gefitinib reversibly inhibits the kinase activity of wild-type EGFR and certain of its activating mutations, preventing autophosphorylation of tyrosine residues linked to the receptor. This blocks further downstream signalling and stops EGFR-dependent cell proliferation. Gefitinib binds more strongly to EGFR carrying an exon 19 deletion or the exon 21 point mutation L858R than it does to wild-type EGFR. It also inhibits IGF and PDGF-mediated signalling at clinically relevant concentrations, though its effects on other tyrosine kinase receptors have not been fully characterized.
Pregnancy & Breastfeeding
There are no adequate and well-controlled studies in pregnant women using Gefitinib. If it is used during pregnancy or if the patient becomes pregnant while receiving this drug, she should be apprised of the potential hazard to the fetus or potential risk for loss of the pregnancy. It is not known whether Gefitinib is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from Gefitinib, women should be advised to discontinue breast-feeding during treatment with Gefitinib.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
ডোজ নির্দেশিকা
⚠️ শুধুমাত্র সরকারি উৎস থেকে নির্দেশিকা পরিসীমা। ব্যক্তিগতকৃত ডোজের জন্য আপনার ডাক্তারের পরামর্শ নিন।
পার্শ্বপ্রতিক্রিয়া ও পারস্পরিক ক্রিয়া
পার্শ্বপ্রতিক্রিয়া
No side-effect data recorded yet.